Propel Bio Management »

Sab Biotherapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $2.4M 653k 3.74

More positions owned by Propel Bio Management

Plains Gp Hldgs Ltd Partnr Int A (PAGP)
Achieve Life Sciences (ACHV)
Phathom Pharmaceuticals (PHAT)
Miragen Therapeutics (VRDN)
Milestone Pharmaceuticals (MIST)
Kyverna Therapeutics (KYTX)
Compass Pathways Sponsored Ads (CMPS)
Inventiva Sa - Ads (IVA)
Delcath Systems Com New (DCTH)
Abeona Therapeutics Com New (ABEO)
Celldex Therapeutics Com New (CLDX)
Nektar Therapeutics Com New (NKTR)
Oculis Holding Ordinary Shares (OCS)
Sab Biotherapeutics Com New (SABS)
Regenxbio Inc equity us cm (RGNX)

View all positions for Propel Bio Management

Top funds holding Sab Biotherapeutics

Vivo Capital
Commodore Capital
RA Capital Management
Woodline Partners
Sessa Capital IM
Vanguard Group
BVF
Propel Bio Management
Leucadia National Corporation
HB Wealth Management
Marshall Wace
Simplify Asset Management
AWM Investment Company
Stempoint Capital
Geode Capital Management

View all funds holding Sab Biotherapeutics